AKT1 and triple-negative breast carcinoma: A phase Ib trial reported that first-line AKT inhibitor Ipatasertib in combination with atezolizumab and paclitaxel or nab-Paclitaxel in patients with advanced triple-negative breast cancer achieved a high ORR of 73% [31].